Backed by 66 billion euros in returns, European life science investment sounds the "loss warning"
- The European Federation of Pharmaceutical Industries and Associations issued a report on Tuesday warning that the current geopolitical and policy environment is putting Europe at risk of losing out in the global competition for life sciences investment.
- The association stressed that strengthening innovation conditions, ensuring new medicines are accessible in a timely and equitable manner, and maintaining Europe’s global competitiveness in the life sciences sector must be promoted as interconnected priorities, rather than being addressed separately.
- According to research commissioned by the association, between 2014 and 2024, Europe invested €11.67 billion in new drug research and development, while cumulative returns from increased labor productivity, contributions from both paid and unpaid work, and hospital cost savings have reached as much as €66 billion—yielding an input-output ratio of nearly 1:5.7.
- Against the backdrop of continued global trade disruption from Trump’s tariff remarks, the STOXX 600 Health Care Index rose 1.2% on Tuesday, reflecting partial market pricing for the sector’s resilience and policy concerns. Going forward, the focus will be on whether the European Union can translate the strategic priorities outlined in the report into concrete legislation and financial support, in order to curb the trend of investment outflows.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Doosan Heavy Industries shipped its first gas turbine to SpaceXAI.
WTI Price Forecast: Bulls seem hesitant near $89.00 amid easing supply risks
BUZZ - India's Kotak Mahindra Bank shares rise on second quarter loan growth; Goldman Sachs reiterates 'Buy' rating
October 6 – ** Shares of India’s Kotak Mahindra Bank KTKM.NS rose 3.3% to 429.80 rupees ** Kotak Mahindra Bank reported a 24.7% increase in net loans for Q2 FY2027 (link) ** Goldman Sachs reiterated its “Buy” rating with a target price of 540 rupees, citing the better-than-expected Q2 performance update ** Given strong deposit growth and organic loan expansion, the bank’s EPS compound annual growth rate (CAGR) estimate for FY2026-29 was raised to 19% ** It was noted that organic loan growth rose from 15% in the previous quarter to 19% year-on-year; this growth momentum is expected to continue, supported by retail loans, SME lending, and commercial banking ** An average of 37 analysts give the stock a “Buy” rating, with a median target price of 470 rupees – data compiled by LSEG ** Year-to-date, the stock is down 5.5% (To assist non-English speakers, Reuters automatically translates its reports into several other languages. Due to the possibility of errors or lack of required context in automated translations, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)
Hyosung TNC stake held by National Pension Service rises to 10.60% from 10.17%
National Pension Service raised its stake in Hyosung TNC to 10.60% as of Sept. 30, 2026. Holding increased to 458,722 shares from 439,981 shares, a net gain of 18,741 shares. Change was driven by on-market purchases and sales, with the reportable event dated Sept. 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyosung TNC Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261006000132), on October 06, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
